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ABSTRACT
Objectives: Hemodialysis-associated bloodstream infection (BSI) is a sig-
niﬁcant public health problem because the number of hemodialysis
patients in Canada had doubled from 1996 to 2005.Our study aimed to
determine the costs of nosocomial BSIs in Canada and estimate the invest-
ment expenses for establishing infection control programs in general hos-
pitals and conduct cost–beneﬁt analysis.
Materials and Methods: The data from the Canadian Nosocomial Infec-
tion Surveillance Program was used to estimate the incidence rate of
nosocomial BSI. We used Canadian Institute of Health Information data to
estimate the extra costs of BSIs per stay across Canada in 2004. The cost
of establishing and maintaining an infection control program in 1985 was
estimated by the US Centers for Disease Control and Prevention and
converted into 2004 Canadian costs. The possible 20% to 30% reduction
of total nosocomial BSIs was hypothesized.
Results: A total of 2524 hemodialysis-associated BSIs were projected
among 15,278 hemodialysis patients in Canada in 2004. The total annual
costs to treat BSIs were estimated to be CDN$49.01 million. Total invest-
ment costs in prevention and human resources were CDN$8.15 million.
The savings of avoidable medical costs after establishing infection control
programs were CDN$14.52 million. The beneﬁt/cost ratio was 1.0 to
1.8:1.
Conclusion: Our study provides evidence that the economic beneﬁt from
implementing infection control programs could be expected to be well in
excess of additional cost postinfection if the reduction of BSI can be
reduced by 20% to 30%. Infection control offered double beneﬁts: saving
money while simultaneously improving the quality of care.
Keywords: bloodstream infection, costs and beneﬁts, health economics,
infection control program.
Introduction
Infections acquired during the use of health-care services are
signiﬁcant public health problems both for the health-care deliv-
ery system and the patient. It has been reported that an estimated
220,000 nosocomial infections are acquired in health-care facili-
ties and 8000 deaths attributable to these infections occur annu-
ally in Canada [1]. The most common nosocomial infections are
surgical wounds, blood stream, and urinary tract infections [2,3].
Taylor et al. reported that the relative risk for bloodstream infec-
tion (BSI) was 2.5 with arteriovenous graft access, 15.5 with
cuffed and tunnelled central venous catheter (CVC) access, and
22.5 with uncuffed CVC access [4].
Nosocomial BSIs result in dramatic increases in economic
cost. In the United States in 2000, approximately 240,000 dialy-
sis patients were treated at 3700 outpatient facilities [5]. The
length of hospital stay was extended by 1 to 4 weeks at a cost of
up to $40,000 (US dollars) per survivor [6–9]. The US Centers
for Disease Control and Prevention (US CDC)estimated that the
excess costs associated with nosocomial infections in US hospi-
tals were $4.5 billion in 1992 [10]. In Canada, there are no
detailed reports on excess costs associated with nosocomial infec-
tions, including BSIs.
The purpose of this study was to determine the cost of noso-
comial BSIs among hemodialysis patients in Canada in 2004. We
also estimated the cost of an infection control program a middle-
sized hospital in Canada in 2004 with the assumption that the
outpatient hemodialysis centre is run out of the hospital. Finally,
we conducted cost–beneﬁt analyses of establishing and running
hospital-based infection control programs in Canada.
Methods
Incidence Rate of BSI in Canada
We have used the data from a prospective surveillance study by
Taylor et al. [11]. During the 6-month follow-up period between
1 December 1998 and 31 May 1999, there were 184 BSIs which
occurred in 133,158 dialysis procedures with an incidence rate of
1.4 cases per 1000 procedures in 11 hemodialysis centres across
Canada.
Estimation of Average Treatment Cost per Stay
(Unit Cost)
According to the surveys of BSIs, out of the 6697 patients in 59
hospitals in the United States, the inpatients and the outpatients
accounted for 60% and 40% of total BSI cases respectively [12].
We used the cost of acute care hospital stays by medical condition
in Canada 2004 to 2005 to estimate the cost of BSI per stay [13].
The cost attributable to the treatment of one case of BSI among
all genders in 2004 was CAD$19,418 per stay. The treatment
costs for the outpatients with BSIs are signiﬁcantly lower. There
was no valid estimate from previous studies. We assumed that the
treatment costs of the outpatients with BSIs were CAD$8,000 to
CAD$12,000. We conducted a sensitivity analysis for the cost–
beneﬁt of different scenarios.
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Total Hemodialysis Patients in Canada in 2004
According to the Canadian Institute for Health Information’s
statistics [14], there were a total of 15,278 hemodialysis patients
and 1,802,922 hemodialysis procedures in Canada in 2004.
Investment Cost of Establishing and Maintaining an
Infection Control Program in a Hospital
In 1975, the US CDC estimated the cost of an infection control
program that was implemented in a 250-bed hospital. These
estimates were subsequently revised in 1979, and further
adjusted to 1985 prices [15]. Personnel resources for a hospital
infection control program included a hospital epidemiologist, an
infection control practitioner (nurse), and one secretary and com-
puter support personnel. There was also nonpersonnel support
such as ofﬁce support, computing support, audiovisual support,
microbiology laboratory support, pathology services, and refer-
ence laboratory testing. We assumed that the infection control
team took 10% of their time investigating BSI [16]. The cost of
establishing and maintaining an infection control program in
1985 US$ was estimated to be US$60,000 [15]. This estimate
(US$60,000) included the costs of employing an infection control
nurse, a part-time physician consult, part-time clerical support,
and the cost of consumables and overheads. So far, there is no
accurate estimate of annual cost for establishing and maintaining
an infection control program in a hospital in Canada. We applied
the unit cost in US$ as a surrogate indicator for our cost analysis.
According to the Bank of Canada’s inﬂation rate statistics, there
was an average annual inﬂation rate of 2.74% during 1985 to
2004, with a total of 67.4% increment in principals. The cost of
establishing and maintaining an infection control program in
2004 in a hospital in Canada was estimated to be US$100,225/
program/year or CAD$133,633 (currency exchange rate on 30
June 2004).
Estimate of the Gross Beneﬁts of Prevention
In the early 1980s, an effective infection control program—
deﬁned by an appropriately trained clinical leader, one infection
control practitioner for 250 beds and a nosocomial surveillance
program—decreased the prevalence of endemic nosocomial
infection in acute care facilities by 30% to 50% [17]. Since most
of hemodialysis patients were outpatients, we assumed that the
BSI prevalence could be prevented by the range of 10% to 30%.
We applied the 10% to 30% reduction in BSIs to calculate the
gross beneﬁts of infection control programs for the health sectors
in Canada.
Results
Average Yearly Cost Attributable to Nosocomial BSIs in
Canada in 2004
There were a total of 1,802,922 hemodialysis procedures in
Canada in 2004. Since the incidence rate was 1.4 cases per 1000
hemodialysis procedures, a total of 2524 BSIs cases were esti-
mated by multiplying 1,802,922 hemodialysis procedures with
1.4 cases/1000 procedures.
Total annual cost to treat 2524 BSIs cases was estimated to be
49.01 million by multiplying 2524 BSIs cases by CAD$19,418
per stay for one BSI case.
Table 1 illustrates the potential beneﬁts of implementing
infection control programs in all hemodialysis units in Canada in
2004 by different scenarios of avoidable BSI prevalence rate. For
example, if the available BSI rate was decreased by 15%, the
potential beneﬁts (cost-savings) for implementing infection
control programs was estimated to be CAD$7.35 million per
year by multiplying CAD$49.01 million by 15%.
Cost for Investment in Prevention Measures and
Human Resources
Suppose that one infection control team is responsible for 250
hemodialysis patients; a total of 15,278 patients would need
about 61 infection control programs across Canada in 2004.
Total running costs for implementing infection control pro-
grams in 2004 was estimated to be CAD$8.15 million by
multiplying 61 infection control programs by CAD$133,633/
program.
Cost–beneﬁt Analysis
There are close correlations between the ratios of beneﬁt/cost and
avoidable BSI rates.
Figure 1 depicts the sensitivity analysis of the ratios of
beneﬁt/cost in different scenarios of avoidable BSI rates. If the
avoidable BSI rate maintained around 17%, the ratio of beneﬁt–
cost would reach to 1:1. If the avoidable BSI rate increased to
30%, the ratio of beneﬁt–cost would reach to 1.80:1.
Sensitivity Analysis for Outpatients
In the previous calculations, we assumed that the treatment costs
of the outpatients were the same as the hospitalized patients. In
reality, hemodialysis outpatients have lower treatment costs for
BSIs. Table 2 illustrates the sensitivity analysis of cost–beneﬁt
ratios by infection control programs among inpatients and out-
patients in Canada. When the outpatients treatment costs are
maintained at CAD$12,000 per BSIs and the inpatients costs are
maintained at CAD$19,418, and the infection control program
can prevent the 20% of the total of BSIs, the beneﬁt/cost ratio
would be 1.01:1.
Discussion
In Canada, the number of hemodialysis patients doubled from
7098 in 1996 to 15,938 in 2005 because of the ageing commu-
nity, diabetes, other underlying causes, and the increased
Table 1 The estimated beneﬁts and investment costs of an infection control program for preventing BSIs infections in a 250-patients hemodialysis unit*
Avoidable BSI
cases (%)
Total therapy cost for
BSI cases (million/year)
Possible cost savings–beneﬁt
(million/year)
Infection control program
investment costs (million/year)
10 49.01 4.90 8.15
15 49.01 7.35 8.15
16.6 49.01 8.17 8.15
20 49.01 9.80 8.15
25 49.01 12.25 8.15
30 49.01 14.70 8.15
*According to The Community and Hospital Infection Control Association-Canada from website: http://www.kgh.on.ca/Infection_Control/Infection_control_RICH.asp.
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incidence of end-stage renal disease [14]. Preventing BSIs in
hemodialysis units has become an important public health task.
Our study estimated that there were approximately 2524 BSIs
(16.52%) that occurred among 15,278 hemodialysis patients in
Canada in 2004, which is comparable to the US estimate of
50,000 BSIs (20.83%) among 240,000 hemodialysis patients in
the US. These facts provide powerful motives to expand surveil-
lance and prevention efforts among hemodialysis patients in the
US and Canada.
Our cost–beneﬁt analysis showed there was a ratio of beneﬁt
to cost (1.80:1) when an infection control program could prevent
the 30% of nosocomial BSIs among the hospitalized patients in
Canada. A beneﬁt–cost of ratio of 1 could be achieved when the
20% of the total nosocomial BSIs are prevented among the
hemodialysis centres in Canada. The beneﬁt to cost ratio will be
higher than estimated if some nosocomial infections in addition
to BSIs are prevented simultaneously by the infection control
programs. From the view of sustainable development in Canada,
preventing hospital infections is the green plan and is worth
implementing across the country.
There are other economic beneﬁts for implementing infection
control programs. These calculations do not account for the
monetary beneﬁt of employee health, drug utilization efforts,
education, exposure evaluation, research, consultation, or certiﬁ-
cate by regulatory agencies. Moreover, nosocomial infections are
sometimes the basis for litigations in lawsuits against hospitals.
Finally, nosocomial infections create dissatisfaction among
patients and can affect the reputation of the institution, both of
which are powerful market forces for a hospital.
There are some limitations with our study. The estimated cost
was drawn from relatively outdated data. For instance, cost for
implementing newer infection control strategies (such as antibi-
otic lock solution and trisodium citrate) may be different and
only be estimated by inﬂation rate. Nosocomial BSIs are associ-
ated with a variety of risk factors such as patient age, use of
intravascular catheters, underlying diseases and other conditions,
severity of illness and knowledge of the health-care worker, and
the infecting microorganisms. For example, the estimated cost
related to nosocomial BSIs varied because of differences in the
patient population studied. It is likely that relatively healthy
patients recovered rapidly from an episode of catheter-associated
bacteraemia with minimal impact on length of stay and cost.
However, nosocomial BSI can signiﬁcantly affect the outcome of
sicker patients. There is a potential overestimation for the inci-
dence rate of BSIs among hemodialysis units in Canada because
there was a high percentage (92%) of CVCs in all infection
episodes during the surveillance period. This is because the uti-
lization of CVCs results in the higher risk of nosocomial BSIs
than the utilization of other hemodialysis procedures. The hypo-
thetical assumption for establishing 61 infection control pro-
grams across Canada for addressing BSIs among all hemodialysis
units may need to be conﬁrmed and veriﬁed. We supposed that
one infection control nurse is responsible for serving 250 hemo-
dialysis patients. In clinical practice, the setting of full-time or
part-time positions is dependant upon each facility’s situation
and ﬁnancial planning.
In the future, increased numbers of outpatient surgical pro-
cedures, shorter hospital stays, utilization of outpatient intrave-
nous infusion services, and the expanding population of
hemodialysis patients, residents of long-term care facilities, and
immunocompromised hosts will inﬂuence the occurrence of BSIs.
These factors must therefore be considered and accounted for in
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Figure 1 The sensitivity analysis of beneﬁt–cost
ratios by different avoidable incidence rates of
bloodstream infections (BSIs).
Table 2 The sensitivity analysis of the cost/beneﬁt of infection control programs among inpatients and outpatients in Canada, 2004
Scenarios
Category of
patients
Treatment
costs per BSI
case (CAD$)
Proportion
(%)
Weighted costs
per BSI
case (CAD$)
Annual BSIs
patients
Annual
treatment
costs (million)
Beneﬁt by
infection control
programs*
(million)
Estimated
investment of infection
control programs†
(million)
Ratio of
beneﬁts
over costs
1 Inpatients 19,418 60 11,651
Outpatients 19,418 40 7,767
19,418 2,524 49.01 9.8 8.15 1.20:1
2 Inpatient 19,418 60 16,451
Outpatient 12,000 40 4,800
16,451 2,524 41.52 8.3 8.15 1.01:1
3 Inpatients 19,418 60 11,651
Outpatients 10,000 40 4,000
15,651 2,524 39.5 7.9 8.15 0.97:1
4 Inpatients 19,418 60 11,651
Outpatients 8,000 40 3,200
14,851 2,524 37.48 7.5 8.15 0.92:1
*We assume that the 20% of total BSIs can be prevented by infection control program.
†It is estimated that 61 infection control programs are needed among hemodialysis centers and each infection control program spends around CAD$133,633 annually.
BSI, bloodstream infection.
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estimating and evaluating the costs associated with nosocomial
BSIs.
Conclusions
Health-care practice has evolved during the last two decades.
Our cost–beneﬁt analysis demonstrated that there is a good
beneﬁt–cost ratio when the infection control program can
prevent 20% to 30% of nosocomial BSIs cases.
Infection control offers dual beneﬁts: it saves money while
simultaneously improving the quality of care. Effective infection
control programs generate monetary beneﬁts by preventing noso-
comial infections and increasing health care efﬁciency by reduc-
ing additional burden. From the standpoint of both the hospital
and of the community, the beneﬁts justify the costs. The eco-
nomic future of infection control depends on its ability to con-
tinue to demonstrate that it is both effective and cost effective.
Source of ﬁnancial support: There is no conﬂict of interest to publish this
manuscript.
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